Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,224,143 papers from all fields of science
Search
Sign In
Create Free Account
Levosimendan
Known as:
Levosimedan
, Levosimendanum
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
Simdax
Broader (1)
simendan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Levosimendan Reduces Lung Injury in a Canine Model of Cardiopulmonary Bypass
Junbo Feng
,
Haiyuan Liu
,
Jiayi Chen
,
Jiyuan Wang
,
Zhuang Liu
,
Shenglin Ge
Korean Circulation Journal
2016
Corpus ID: 6003428
Background and Objectives To explore the lung-protective effect of levosimendan (LS) during cardiopulmonary bypass in a canine…
Expand
2015
2015
The histopathological effects of levosimendan on liver injury induced by myocardial ischemia and reperfusion.
G. L. Oktar
,
N. Demir Amac
,
+6 authors
T. Tatar
Bratislava Medical Journal
2015
Corpus ID: 33432402
BACKGROUND The aim of this study was to evaluate the histological and immunohistochemical effects of levosimendan on liver injury…
Expand
2014
2014
The effect of levosimendan combined with 20% lipid emulsion treatment on survival from bupivacaine induced toxicity in experiment.
G. Gokahmetoglu
,
R. Aksu
,
C. Biçer
,
K. Darçın
,
F. Uğur
Bratislava Medical Journal
2014
Corpus ID: 23186229
BACKGROUND Recent reports demonstrated that levosimendan improved post-resuscitation myocardial function in rat and pig models…
Expand
2012
2012
[Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension].
T. Martyniuk
,
O. Arkhipova
,
E. Kobal
,
N. Danilov
,
I. Chazova
Терапевтический архив
2012
Corpus ID: 12108518
AIM To evaluate the efficiency and safety of intravenous infusion of levosimendan in patients with idiopathic pulmonary…
Expand
2010
2010
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
M. Tek
,
Y. Cavusoglu
,
+5 authors
N. Ata
Turk Kardiyoloji Dernegi arsivi : Turk…
2010
Corpus ID: 24483739
OBJECTIVES Unlike traditional inotropic agents, levosimendan is thought to have a lower potential to induce arrhythmias because…
Expand
2009
2009
Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
Y. Cavusoglu
,
Ayse Beyaztas
,
Alparslan Birdane
,
N. Ata
Journal of Cardiovascular Medicine
2009
Corpus ID: 30857141
Currently, prostacyclin, endothelin receptor antagonists and phosphodiesterase inhibitors are recommended therapy in idiopathic…
Expand
2008
2008
Effects of levosimendan on myocardial ischaemia‐reperfusion injury
D. Yapıcı
,
Z. Altunkan
,
+7 authors
U. Oral
European Journal of Anaesthesiology
2008
Corpus ID: 44461692
Background and objective: Levosimendan has a cardioprotective action by inducing coronary vasodilatation and preconditioning by…
Expand
2003
2003
Levosimendan compared with dobutamine in low output patients.
Nieminen Ms
2003
Corpus ID: 57501440
There are 2 studies which have investigated the hemodynamic efficacy of levosimendan compared to dobutamine in congestive heart…
Expand
2003
2003
Wirkt Levosimendan bei der operativen Versorgung des akuten Koronarsyndroms inoprotektiv
A. Lehmann
,
J. Boldt
,
J. Lang
,
F. Isgro
,
M. Blome
2003
Corpus ID: 76807723
: Levosimendan, is a new calcium sensitiser with 2 major effects. First, levosimendan acts as a positive inotropic agent by…
Expand
1995
1995
Safety of levosimendan and other calcium sensitizers.
Lasse Lehtonen
,
Pirjo Mills-Owens
,
J. Akkila
Journal of Cardiovascular Pharmacology
1995
Corpus ID: 33308858
Levosimendan belongs to a new group of heart failure drugs, the calcium sensitizers. Because these compounds are not yet…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE